Erythema Nodosum — VA Disability Rating (Rated by Analogy, DC 7899-7806)
Diagnostic Code 7899-7806 · 38 CFR §4.118
What Is It?
Erythema nodosum is a panniculitis — an inflammation of the fat layer beneath the skin — that produces tender, deep, red-purple nodules, classically on the shins. The nodules do not ulcerate and do not scar, but they are genuinely painful, they make standing and walking difficult while active, and they are usually accompanied by fever and joint aching. Roughly half of cases are idiopathic; the rest are reactions to something else — sarcoidosis above all, plus streptococcal infection, tuberculosis, inflammatory bowel disease, coccidioidomycosis, and a long list of medications including sulfonamides and oral contraceptives. Erythema nodosum is not listed anywhere in 38 CFR §4.118. Under 38 CFR §4.20 an unlisted condition is rated by analogy to a closely related listed disease, and §4.27 requires a built-up code for it — here 7899-7806, which routes the evaluation through the General Rating Formula for the Skin. The practical consequence is that the rating turns on body surface area and systemic therapy duration, which fits erythema nodosum poorly, so the strongest claims lean on the underlying cause and on separate ratings for what that cause does.
Rating Criteria
| Rating | Criteria |
|---|---|
| 60% | Characteristic nodular lesions involving more than 40 percent of the entire body, or more than 40 percent of exposed areas affected; or, constant or near-constant systemic therapy required over the past 12-month period. This is the maximum schedular evaluation under the General Rating Formula for the Skin. |
| 30% | Characteristic nodular lesions involving 20 to 40 percent of the entire body, or 20 to 40 percent of exposed areas affected; or, systemic therapy required for a total duration of six weeks or more, but not constantly, over the past 12-month period. |
| 10% | Characteristic nodular lesions involving at least 5 percent but less than 20 percent of the entire body, or at least 5 percent but less than 20 percent of exposed areas affected; or, intermittent systemic therapy — including but not limited to corticosteroids, phototherapy, retinoids, biologics, photochemotherapy, PUVA, or other immunosuppressive drugs — required for a total duration of less than six weeks over the past 12-month period. |
| 0% | No more than topical therapy required over the past 12-month period, and characteristic nodular lesions involving less than 5 percent of the entire body or less than 5 percent of exposed areas affected. |
Evidence Needed
Two things need proving: the condition and, almost always more valuably, what is behind it. For the condition itself, a dermatology diagnosis and, where performed, a deep incisional biopsy showing septal panniculitis without vasculitis. For the rating, documentation of how much skin surface is involved during a flare and a complete record of systemic therapy — oral corticosteroids, potassium iodide, colchicine, NSAIDs — with the total number of weeks per year, because duration is what separates 10 percent from 30 percent from 60 percent. For the underlying cause, the workup itself is the evidence: chest imaging and ACE level for sarcoidosis, streptococcal serology, tuberculin or interferon-gamma testing, gastrointestinal workup for inflammatory bowel disease, and coccidioidomycosis serology for veterans who served in the desert Southwest. Photographs during a flare are important because the nodules resolve completely.
C&P Exam Tips
Ask the examiner to record the percentage of total body and of exposed areas involved during a flare, not on the day of the exam, and bring dated photographs to support it. Give a precise systemic-therapy history in weeks per year — that number often decides the rating, and "I take prednisone sometimes" does not produce a number. Make the point directly that erythema nodosum is a marker for a systemic disease and ask whether the underlying cause has been identified; if sarcoidosis or inflammatory bowel disease is behind it, that condition carries a far higher rating ceiling than the skin code ever will. Describe the functional impact honestly — the nodules are on the shins, they hurt to stand on, and time on your feet during a flare is the concrete measure of that.
How to File
File on VA Form 21-526EZ as erythema nodosum and expect the VA to assign a built-up analogous code such as 7899-7806. Attach the dermatology diagnosis, biopsy if performed, flare photographs, and a systemic therapy history with durations. In the same claim, file the underlying condition separately by name — sarcoidosis under DC 6846, inflammatory bowel disease under the digestive codes, coccidioidomycosis under DC 6835 — because those are usually the higher-value claims. If a medication prescribed for a service-connected condition triggered the flares, file that as a secondary claim and name the drug.
Common Mistakes
The biggest missed opportunity is filing the rash and not the disease behind it. Erythema nodosum is frequently the first visible sign of sarcoidosis, and sarcoidosis under DC 6846 has a rating ceiling many times higher than the skin formula's 60 percent. A veteran who claims only the skin condition can end up at 10 percent for a disease that should have been developed as a systemic claim. The second mistake is not tracking systemic therapy duration in weeks — the criteria are written in weeks and the record usually is not. The third is being examined during a quiet period with no flare photographs, which produces a body-surface-area figure of essentially zero. The fourth is expecting to find a DC 7827 rating for erythema nodosum on the decision letter; DC 7827 is erythema multiforme, and erythema nodosum is properly rated by analogy under a built-up code.
Frequently Asked Questions
Why does erythema nodosum not have its own diagnostic code?
Because 38 CFR §4.118 lists a limited set of skin diseases and erythema nodosum is not among them. 38 CFR §4.20 provides that an unlisted condition is rated by analogy to a closely related disease with comparable symptoms and functional impairment, and §4.27 requires the VA to build up a code for it — the first two digits identify the body system, the last two are "99," and a hyphenated second code shows what it was rated as. So you will typically see 7899-7806 on the decision.
What does the code 7899-7806 mean?
The "78" identifies the skin system, the "99" flags an unlisted condition, and the "7806" after the hyphen names the listed disease the VA used as the analogy — dermatitis, which is rated under the General Rating Formula for the Skin. Reading it left to right: an unlisted skin condition, rated as if it were dermatitis. Other analogous codes appear on erythema nodosum decisions too, and you can argue for a different analogy if it fits your case better.
Should I claim sarcoidosis as well?
If there is any indication of it, yes. Erythema nodosum is one of the classic presenting signs of sarcoidosis, and sarcoidosis is rated under DC 6846 with a schedular ceiling of 100 percent when there is pulmonary involvement with cor pulmonale or systemic high-dose steroid requirement. Chest imaging and an ACE level are the starting point. The skin claim and the sarcoidosis claim are separate issues and should both be filed.
How is the rating calculated if the nodules come and go?
The General Rating Formula looks back over a 12-month period, so it is designed to capture an intermittent condition — but only if the record documents the flares. The percentage of body surface involved is measured at flare, not at rest, and the systemic therapy criterion is expressed as total duration over the past twelve months. Dated photographs and a therapy log covering a full year are what turn an intermittent condition into a rateable one.